Brief: Denali Therapeutics Announces U.S. FDA Approval Of Avlayah™ (Tividenofusp Alfa-Eknm) For Treatment Of Hunter Syndrome (Mps Ii)
25/03/2026 16:02
March 25 (Reuters) - Denali Therapeutics Inc DNLI.O: DENALI THERAPEUTICS ANNOUNCES U.S. FDA APPROVAL OF AVLAYAH™ (TIVIDENOFUSP ALFA-EKNM) FOR TREATMENT OF HUNTER SYNDROME (MPS II) DENALI THERAPEUTICS INC - AVLAYAH TO BE AVAILABLE IN U.S. SHORTLY AFTER APPROVAL, ADMINISTERED ONCE WEEKLY DENALI THERAPEUTICS INC - AWARDED RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER WITH FDA APPROVAL Source text: ID:nGNX7tn4T Further company coverage: DNLI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Denali Therapeutics
See all newsDenali Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive
U.S. STOCKS ON THE MOVE-IMAX, Novo Nordisk, PC makers